RU2486179C2 - Аналоги тиазолидиндиона для лечения диабета и дислипидемии - Google Patents

Аналоги тиазолидиндиона для лечения диабета и дислипидемии Download PDF

Info

Publication number
RU2486179C2
RU2486179C2 RU2010114727/04A RU2010114727A RU2486179C2 RU 2486179 C2 RU2486179 C2 RU 2486179C2 RU 2010114727/04 A RU2010114727/04 A RU 2010114727/04A RU 2010114727 A RU2010114727 A RU 2010114727A RU 2486179 C2 RU2486179 C2 RU 2486179C2
Authority
RU
Russia
Prior art keywords
group
mmol
vacuo
alkyl
evaporated
Prior art date
Application number
RU2010114727/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010114727A (ru
Inventor
Джерард Р. КОЛКА
Роберт К. ГЭДВУД
Тим ПАРКЕР
Original Assignee
МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи filed Critical МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи
Publication of RU2010114727A publication Critical patent/RU2010114727A/ru
Application granted granted Critical
Publication of RU2486179C2 publication Critical patent/RU2486179C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010114727/04A 2007-09-14 2008-09-15 Аналоги тиазолидиндиона для лечения диабета и дислипидемии RU2486179C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97263907P 2007-09-14 2007-09-14
US60/972,639 2007-09-14
PCT/US2008/010723 WO2009038681A1 (en) 2007-09-14 2008-09-15 Thiazolidinedione analogues for the treatment of hypertension

Publications (2)

Publication Number Publication Date
RU2010114727A RU2010114727A (ru) 2011-10-20
RU2486179C2 true RU2486179C2 (ru) 2013-06-27

Family

ID=40239575

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010114727/04A RU2486179C2 (ru) 2007-09-14 2008-09-15 Аналоги тиазолидиндиона для лечения диабета и дислипидемии

Country Status (15)

Country Link
US (1) US8067450B2 (enExample)
EP (1) EP2203433B1 (enExample)
JP (1) JP5371988B2 (enExample)
KR (1) KR101537830B1 (enExample)
CN (1) CN101848901B (enExample)
AU (1) AU2008301905B2 (enExample)
BR (1) BRPI0817096B8 (enExample)
CA (1) CA2699289C (enExample)
ES (1) ES2398313T3 (enExample)
IL (1) IL204440A (enExample)
MX (1) MX2010002820A (enExample)
NZ (2) NZ597381A (enExample)
PL (1) PL2203433T3 (enExample)
RU (1) RU2486179C2 (enExample)
WO (1) WO2009038681A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149271B2 (ja) 2006-03-16 2013-02-20 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
RU2445957C2 (ru) 2006-03-16 2012-03-27 Метаболик Солюшнз Девелопмент Компани Аналоги тиазолидиндиона
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
AU2008301905B2 (en) 2007-09-14 2013-06-27 Cirius Therapeutics, Inc. Thiazolidinedione analogues for the treatment of hypertension
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
NZ600421A (en) * 2009-12-15 2014-06-27 Metabolic Solutions Dev Co Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
AU2010340058A1 (en) * 2009-12-15 2012-06-21 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
KR20120092714A (ko) * 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 비만 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
HUE038042T2 (hu) * 2009-12-15 2018-09-28 Cirius Therapeutics Inc PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX2012012092A (es) * 2010-04-19 2012-12-17 Metabolic Solutions Dev Co Llc Sintesis novedosa para compuestos de tiazolidinadiona.
EP2560615A1 (en) * 2010-04-21 2013-02-27 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
HUE029488T2 (en) * 2010-08-10 2017-02-28 Metabolic Solutions Dev Co Llc Synthesis of Thiazolidinedione Compounds
HUE031424T2 (en) 2010-08-10 2017-07-28 Octeta Therapeutics Llc New synthesis of thiazolidinedione compounds
WO2012109495A1 (en) * 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
MX2016000724A (es) 2013-07-22 2016-04-13 Metabolic Solutions Dev Co Llc Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US20210038566A1 (en) 2018-02-08 2021-02-11 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) * 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses
EP0749751A2 (en) * 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes
RU2114844C1 (ru) * 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
WO2007109037A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
CA2106967C (en) 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
CA2371391A1 (en) * 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
DK1192137T3 (da) 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US7009057B2 (en) 2001-04-26 2006-03-07 Zentiva A.S. Method for obtaining pioglitazone as an antidiabetic agent
US7135485B2 (en) * 2001-09-28 2006-11-14 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
WO2004007490A2 (en) 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
JPWO2004082715A1 (ja) * 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2005015477A (ja) * 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20070078170A1 (en) * 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US7777038B2 (en) 2004-09-28 2010-08-17 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
CA2646170A1 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
RU2445957C2 (ru) 2006-03-16 2012-03-27 Метаболик Солюшнз Девелопмент Компани Аналоги тиазолидиндиона
AU2008301905B2 (en) 2007-09-14 2013-06-27 Cirius Therapeutics, Inc. Thiazolidinedione analogues for the treatment of hypertension
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) * 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses
RU2114844C1 (ru) * 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
EP0749751A2 (en) * 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes
RU2198682C2 (ru) * 1995-06-20 2003-02-20 Такеда Кемикал Индастриз Лтд. Фармацевтическая композиция
WO2007109037A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERBER P. et al.: "Effects of pioglitazone on metabolic control and blood pressure: A randomized study in patients with type 2 diabetes mellitus", CURRENT MEDICAL RESEARCH AND OPINION, 2003, vol.19, no.6, p.532-539. TANIS S.P. et al.: "Synthesis and biological activity of metabolites of the antidiabetic antihyperglycemic agent Pioglitazone", JOURNAL OF MEDICINAL CHEMISTRY, 1996, vol.39, no.26, p.5053-5063. *
TAKASHI SOHDA et al.: "Studies on antidiabetic agents. II.1) Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives", CHEMICAL & PHARMACEUTICAL BULLETIN, 1982, vol.30, no.10, pp.3580-3600. *
TAKASHI SOHDA et al.: "Studies on antidiabetic agents. II.1) Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives", CHEMICAL & PHARMACEUTICAL BULLETIN, 1982, vol.30, no.10, pp.3580-3600. GERBER P. et al.: "Effects of pioglitazone on metabolic control and blood pressure: A randomized study in patients with type 2 diabetes mellitus", CURRENT MEDICAL RESEARCH AND OPINION, 2003, vol.19, no.6, p.532-539. TANIS S.P. et al.: "Synthesis and biological activity of metabolites of the antidiabetic antihyperglycemic agent Pioglitazone", JOURNAL OF MEDICINAL CHEMISTRY, 1996, vol.39, no.26, p.5053-5063. *

Also Published As

Publication number Publication date
BRPI0817096B1 (pt) 2020-11-10
BRPI0817096B8 (pt) 2021-05-25
CA2699289A1 (en) 2009-03-26
AU2008301905B2 (en) 2013-06-27
IL204440A (en) 2013-05-30
CN101848901A (zh) 2010-09-29
MX2010002820A (es) 2010-04-01
RU2010114727A (ru) 2011-10-20
BRPI0817096A2 (pt) 2017-05-02
NZ583889A (en) 2012-01-12
BRPI0817096A8 (pt) 2017-10-10
KR101537830B1 (ko) 2015-07-17
KR20100075915A (ko) 2010-07-05
PL2203433T3 (pl) 2013-04-30
AU2008301905A1 (en) 2009-03-26
CA2699289C (en) 2016-01-19
JP5371988B2 (ja) 2013-12-18
ES2398313T3 (es) 2013-03-15
HK1146484A1 (en) 2011-06-10
WO2009038681A1 (en) 2009-03-26
US8067450B2 (en) 2011-11-29
CN101848901B (zh) 2012-11-21
NZ597381A (en) 2013-03-28
JP2010539171A (ja) 2010-12-16
US20100222399A1 (en) 2010-09-02
EP2203433A1 (en) 2010-07-07
EP2203433B1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
RU2486179C2 (ru) Аналоги тиазолидиндиона для лечения диабета и дислипидемии
CA2646207C (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
JP2010539171A5 (enExample)
JP5149271B2 (ja) 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
WO2010105048A9 (en) Thiazolidinedione analogues
EP2512475A1 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
JP2013514369A (ja) 糖尿病および他の代謝性疾患を処置するための、ｐｐａｒ温存チアゾリジンジオンおよび組み合わせ物
WO2011084453A1 (en) Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
JP2013525362A (ja) チアゾリジンジオン類似体
US8304441B2 (en) Thiazolidinedione analogues for the treatment of metabolic diseases
AU2013200104B2 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
WO2012178142A1 (en) Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
HK1146484B (en) Thiazolidinedione analogues for the treatment of hypertension
HK1178066A (en) Thiazolidinedione analogues

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20160810

PD4A Correction of name of patent owner